Drug discovery & development
- To provide management services to Theryte since February 2007 to assist the founder in commercialising his technology. Dr Bill Primrose of Ithaka was part-time CEO of Theryte and led the development of a new business plan, negotiations of deals with key CROs and collaborations with other research organisations. He also managed the R&D, including out-sourcing target identification, synthetic chemistry, pharmacokinetics, toxicology and in vivo studies.
- Dr Bill Primrose has obtained further equity financing for the business from new angel investors and existing investors, and grant funding to complete a set of experiments designed to demonstrate proof-of-concept for Theryte's lead molecule.
- To perform two business and technical due diligence assessments on Gentronix, a University of Manchester spin-out developing novel toxicology tests for use in pharmaceutical development.
- Investment of over £1M into Gentronix.